225 related articles for article (PubMed ID: 33159471)
1. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Wunsch E; Norman GL; Milkiewicz M; Krawczyk M; Bentow C; Shums Z; Mahler M; Lopens S; Reinhold D; Franke A; Schramm C; Roggenbuck D; Milkiewicz P
Aliment Pharmacol Ther; 2021 Jan; 53(2):302-313. PubMed ID: 33159471
[TBL] [Abstract][Full Text] [Related]
2. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
3. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).
Stinton LM; Bentow C; Mahler M; Norman GL; Eksteen B; Mason AL; Kaplan GG; Lindkvist B; Hirschfield GM; Milkiewicz P; Cheung A; Janssen HL; Fritzler MJ
PLoS One; 2014; 9(11):e112877. PubMed ID: 25397578
[TBL] [Abstract][Full Text] [Related]
4. Anti-Proteinase 3 Antibodies as a Biomarker for Ulcerative Colitis and Primary Sclerosing Cholangitis in Children.
Laass MW; Ziesmann J; de Laffolie J; Röber N; Conrad K
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):463-470. PubMed ID: 35703948
[TBL] [Abstract][Full Text] [Related]
5. PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis.
Lopens S; Wunsch E; Milkiewicz M; Röber N; Zarske G; Nasser A; Conrad K; Laass M; Rödiger S; Krawczyk M; Roggenbuck D; Milkiewicz P
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36359524
[TBL] [Abstract][Full Text] [Related]
6. Serological biomarkers for management of primary sclerosing cholangitis.
Tornai D; Ven PL; Lakatos PL; Papp M
World J Gastroenterol; 2022 Jun; 28(21):2291-2301. PubMed ID: 35800183
[TBL] [Abstract][Full Text] [Related]
7. The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.
Lopens S; Krawczyk M; Papp M; Milkiewicz P; Schierack P; Liu Y; Wunsch E; Conrad K; Roggenbuck D
Auto Immun Highlights; 2020 Mar; 11(1):6. PubMed ID: 32178720
[TBL] [Abstract][Full Text] [Related]
8. Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis.
Lenzen H; Weismüller TJ; Negm AA; Wlecke J; Loges S; Strassburg CP; Manns MP; Lankisch TO
Scand J Gastroenterol; 2013 Oct; 48(10):1205-12. PubMed ID: 23957616
[TBL] [Abstract][Full Text] [Related]
9. Editorial: serologic antibodies in primary sclerosing cholangitis-a tell-tale sign of compromised gut-liver immunity? Authors' reply.
Wunsch E; Milkiewicz P
Aliment Pharmacol Ther; 2021 Jan; 53(2):352-353. PubMed ID: 33368503
[No Abstract] [Full Text] [Related]
10. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.
Papp M; Sipeki N; Vitalis Z; Tornai T; Altorjay I; Tornai I; Udvardy M; Fechner K; Jacobsen S; Teegen B; Sumegi A; Veres G; Lakatos PL; Kappelmayer J; Antal-Szalmas P
J Hepatol; 2013 Sep; 59(3):457-66. PubMed ID: 23639483
[TBL] [Abstract][Full Text] [Related]
11. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.
Goss JA; Shackleton CR; Farmer DG; Arnaout WS; Seu P; Markowitz JS; Martin P; Stribling RJ; Goldstein LI; Busuttil RW
Ann Surg; 1997 May; 225(5):472-81; discussion 481-3. PubMed ID: 9193175
[TBL] [Abstract][Full Text] [Related]
12. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis.
Bergquist A; Broomé U
Best Pract Res Clin Gastroenterol; 2001 Aug; 15(4):643-56. PubMed ID: 11492973
[TBL] [Abstract][Full Text] [Related]
13. IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.
Sandin C; Eriksson P; Segelmark M; Skogh T; Kastbom A
Clin Exp Immunol; 2016 May; 184(2):208-15. PubMed ID: 26762653
[TBL] [Abstract][Full Text] [Related]
14. A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases.
Lee AS; Finkielman JD; Peikert T; Hummel AM; Viss MA; Specks U
J Immunol Methods; 2005 Dec; 307(1-2):62-72. PubMed ID: 16242707
[TBL] [Abstract][Full Text] [Related]
15. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
Tornai T; Tornai D; Sipeki N; Tornai I; Alsulaimani R; Fechner K; Roggenbuck D; Norman GL; Veres G; Par G; Par A; Szalay F; Lakatos PL; Antal-Szalmas P; Papp M
Sci Rep; 2018 Jan; 8(1):399. PubMed ID: 29321484
[TBL] [Abstract][Full Text] [Related]
16. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK).
Lindgren S; Nilsson S; Nässberger L; Verbaan H; Wieslander J
J Gastroenterol Hepatol; 2000 Apr; 15(4):437-42. PubMed ID: 10824890
[TBL] [Abstract][Full Text] [Related]
17. Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?
Rizvi S; Yang JD; Gores GJ
Gut; 2017 Jan; 66(1):4-5. PubMed ID: 27587361
[No Abstract] [Full Text] [Related]
18. Anti-neutrophil cytoplasmic antibodies (ANCA) specific for one or several antigens: useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis.
Dobric S; Popovic D; Nikolic M; Andrejevic S; Spuran M; Bonaci-Nikolic B
Clin Chem Lab Med; 2011 Nov; 50(3):503-9. PubMed ID: 22107137
[TBL] [Abstract][Full Text] [Related]
19. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.
Schwarze C; Terjung B; Lilienweiss P; Beuers U; Herzog V; Sauerbruch T; Spengler U
Clin Exp Immunol; 2003 Aug; 133(2):283-9. PubMed ID: 12869036
[TBL] [Abstract][Full Text] [Related]
20. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.
Moxey J; Huq M; Proudman S; Sahhar J; Ngian GS; Walker J; Strickland G; Wilson M; Ross L; Major G; Roddy J; Stevens W; Nikpour M
Arthritis Res Ther; 2019 Feb; 21(1):57. PubMed ID: 30764870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
